Study of Decitabine, Lisaftoclax, and Olverembatinib for Advanced CML and Ph+ AML
This study is testing a combination of three drugs: decitabine, lisaftoclax, and olverembatinib. It's for people with advanced chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) who have not responded to or cannot tolerate previous treatments. The main goal is to find the safest and most effective doses of lisaftoclax and olverembatinib when given with decitabine. Researchers will also look at how well this drug combination helps patients achieve remission or improve their condition. You can join if you are 18 or older, have one of these conditions, and meet specific health requirements. The study plans to enroll 30 participants.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It aims to find the right dosage of the study drugs.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be monitored through study completion, which is expected to be an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nicholas Short, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0